Pre-existing type 2 diabetes is associated with increased all-cause death independently of echocardiographic predictors of poor prognosis only in ischemic heart disease.


Journal

Nutrition, metabolism, and cardiovascular diseases : NMCD
ISSN: 1590-3729
Titre abrégé: Nutr Metab Cardiovasc Dis
Pays: Netherlands
ID NLM: 9111474

Informations de publication

Date de publication:
30 10 2020
Historique:
received: 30 05 2020
revised: 27 06 2020
accepted: 06 07 2020
pubmed: 10 9 2020
medline: 15 12 2020
entrez: 9 9 2020
Statut: ppublish

Résumé

It is unknown whether the prognostic role of diabetes (T2DM) in outpatients with chronic heart failure (CHF) is independent of the most important echocardiographic markers of poor prognosis. The aims of this analysis were to evaluate whether T2DM modifies the risk of mortality in CHF patients stratified by etiology of disease or by right-ventricular to pulmonary arterial coupling at echocardiography and to evaluate how T2DM interacts with the prognostic role of cardiac plasma biomarkers. This is a retrospective analysis of 1627 CHF outpatients who underwent a complete echocardiographic examination. During a median follow-up period of 63 months 255 patients died. Poor right-ventricular to pulmonary arterial coupling and reduced left ventricular ejection fraction were independent predictors of outcome, whereas ischemic etiology and T2DM were not. T2DM interacted with etiology increasing the risk of mortality by 32% among patients with ischemic disease (p = 0.003). Elevated hsTNI plasma levels were associated with poor survival in T2DM but not in non-diabetic patients. T2DM signals a worse outcome in ischemic CHF patients regardless of the echocardiographic phenotype. High plasma levels of hsTNI are stronger predictors of mortality in CHF patients with T2DM than in patients without diabetes.

Sections du résumé

BACKGROUND AND AIMS
It is unknown whether the prognostic role of diabetes (T2DM) in outpatients with chronic heart failure (CHF) is independent of the most important echocardiographic markers of poor prognosis. The aims of this analysis were to evaluate whether T2DM modifies the risk of mortality in CHF patients stratified by etiology of disease or by right-ventricular to pulmonary arterial coupling at echocardiography and to evaluate how T2DM interacts with the prognostic role of cardiac plasma biomarkers.
METHODS AND RESULTS
This is a retrospective analysis of 1627 CHF outpatients who underwent a complete echocardiographic examination. During a median follow-up period of 63 months 255 patients died. Poor right-ventricular to pulmonary arterial coupling and reduced left ventricular ejection fraction were independent predictors of outcome, whereas ischemic etiology and T2DM were not. T2DM interacted with etiology increasing the risk of mortality by 32% among patients with ischemic disease (p = 0.003). Elevated hsTNI plasma levels were associated with poor survival in T2DM but not in non-diabetic patients.
CONCLUSION
T2DM signals a worse outcome in ischemic CHF patients regardless of the echocardiographic phenotype. High plasma levels of hsTNI are stronger predictors of mortality in CHF patients with T2DM than in patients without diabetes.

Identifiants

pubmed: 32900568
pii: S0939-4753(20)30283-0
doi: 10.1016/j.numecd.2020.07.008
pii:
doi:

Substances chimiques

Biomarkers 0
Troponin I 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2036-2040

Informations de copyright

Copyright © 2020. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None declared.

Auteurs

Stefano Ghio (S)

Division of Cardiology, Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia, Italy. Electronic address: s.ghio@smatteo.pv.it.

Catherine Klersy (C)

Clinical Epidemiology & Biometrys, Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia, Italy.

Erberto Carluccio (E)

Division of Cardiology, University of Perugia, School of Medicine, Perugia, Italy.

Angela B Scardovi (AB)

Cardiologia, Ospedale Santo Spirito, Roma, Italy.

Laura Scelsi (L)

Division of Cardiology, Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia, Italy.

Calogero Falletta (C)

Cardiology Unit, Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation, I.R.C.C.S. - ISMETT, Palermo, Italy.

Andrea Rossi (A)

Department of Biomedical and Surgical Sciences, Cardiology Section, University of Verona, Verona, Italy.

Pompilio Faggiano (P)

Department of Cardiology, Spedali Civili Hospital and University of Brescia, Italy.

Egidio Traversi (E)

Division of Cardiology, Fondazione Salvatore Maugeri, IRCCS, Montescano, Italy.

Olga Vriz (O)

Heart Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

Marco Guazzi (M)

Heart Failure Unit and Cardiopulmonary Laboratory, Cardiology, I.R.C.C.S. Policlinico San Donato University Hospital, Milano, Italy.

Frank L Dini (FL)

Cardiac, Thoracic and Vascular Department, University of Pisa, Italy.

Giovanni Targher (G)

Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.

Pier L Temporelli (PL)

Division of Cardiology, Fondazione Salvatore Maugeri, IRCCS, Veruno, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH